Mountain Pacific Investment Advisers Inc. ID Has $22.12 Million Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Mountain Pacific Investment Advisers Inc. ID increased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.5% in the fourth quarter, Holdings Channel.com reports. The firm owned 41,671 shares of the medical research company’s stock after purchasing an additional 620 shares during the quarter. Thermo Fisher Scientific makes up 1.4% of Mountain Pacific Investment Advisers Inc. ID’s holdings, making the stock its 26th largest holding. Mountain Pacific Investment Advisers Inc. ID’s holdings in Thermo Fisher Scientific were worth $22,118,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of TMO. Raleigh Capital Management Inc. raised its holdings in shares of Thermo Fisher Scientific by 49.1% during the third quarter. Raleigh Capital Management Inc. now owns 82 shares of the medical research company’s stock worth $41,000 after acquiring an additional 27 shares during the period. Cedar Mountain Advisors LLC raised its stake in shares of Thermo Fisher Scientific by 107.0% in the 4th quarter. Cedar Mountain Advisors LLC now owns 89 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 46 shares during the period. Operose Advisors LLC lifted its holdings in shares of Thermo Fisher Scientific by 250.0% in the third quarter. Operose Advisors LLC now owns 105 shares of the medical research company’s stock valued at $53,000 after purchasing an additional 75 shares in the last quarter. Financial Connections Group Inc. bought a new position in shares of Thermo Fisher Scientific during the fourth quarter worth about $53,000. Finally, Valley National Advisers Inc. raised its position in Thermo Fisher Scientific by 40.5% in the 3rd quarter. Valley National Advisers Inc. now owns 111 shares of the medical research company’s stock valued at $56,000 after buying an additional 32 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock opened at $573.60 on Friday. The company has a market capitalization of $218.95 billion, a price-to-earnings ratio of 36.79, a PEG ratio of 2.44 and a beta of 0.80. The stock’s 50 day moving average is $573.60 and its 200-day moving average is $529.90. The company has a current ratio of 1.70, a quick ratio of 1.39 and a debt-to-equity ratio of 0.68. Thermo Fisher Scientific Inc. has a 12 month low of $415.60 and a 12 month high of $603.82.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, topping the consensus estimate of $4.70 by $0.41. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. The firm had revenue of $10.35 billion for the quarter, compared to analysts’ expectations of $10.14 billion. Equities research analysts expect that Thermo Fisher Scientific Inc. will post 21.52 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were issued a dividend of $0.39 per share. The ex-dividend date of this dividend was Thursday, March 14th. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 annualized dividend and a dividend yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.01%.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on TMO shares. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Thermo Fisher Scientific from $600.00 to $610.00 and gave the company a “buy” rating in a report on Thursday. HSBC boosted their price target on shares of Thermo Fisher Scientific from $630.00 to $660.00 and gave the stock a “buy” rating in a research report on Wednesday, April 17th. JPMorgan Chase & Co. lifted their target price on Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a research report on Thursday. Evercore ISI increased their price target on Thermo Fisher Scientific from $575.00 to $610.00 and gave the company an “outperform” rating in a research report on Thursday, April 4th. Finally, The Goldman Sachs Group boosted their price target on Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a “buy” rating in a research report on Wednesday, April 10th. Five equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $606.76.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, Director Debora L. Spar sold 164 shares of Thermo Fisher Scientific stock in a transaction on Monday, February 12th. The stock was sold at an average price of $546.97, for a total value of $89,703.08. Following the completion of the transaction, the director now directly owns 1,207 shares of the company’s stock, valued at approximately $660,192.79. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $555.63, for a total transaction of $5,556,300.00. Following the completion of the sale, the chief executive officer now directly owns 49,155 shares in the company, valued at $27,311,992.65. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Debora L. Spar sold 164 shares of Thermo Fisher Scientific stock in a transaction on Monday, February 12th. The shares were sold at an average price of $546.97, for a total value of $89,703.08. Following the completion of the transaction, the director now owns 1,207 shares in the company, valued at approximately $660,192.79. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 50,277 shares of company stock worth $28,513,384. Company insiders own 0.32% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.